PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 5, 2008Journal of Clinical Oncology2,930 citationsOpen Access

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

CLCornelia LiedtkeThe University of Texas MD Anderson Cancer CenterCMChafika MazouniThe University of Texas MD Anderson Cancer CenterKHKenneth R. HessThe University of Texas MD Anderson Cancer Center

Key Points

  • To evaluate the impact of pathologic response following neoadjuvant chemotherapy on long-term survival outcomes in patients with triple-negative breast cancer compared to non-triple-negative breast cancer.
  • Assessed response to neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) versus non-TNBC.
  • Categorized outcomes by the presence of pathologic complete response (pCR) versus residual disease (RD) and monitored survival.
  • Patients with TNBC achieved higher pCR rates than those with non-TNBC, with pCR conferring excellent long-term survival.
  • Patients with residual disease following neoadjuvant chemotherapy experienced significantly worse survival if they had TNBC compared with non-TNBC, predominantly within the first 3 years.

Abstract

Patients with TNBC have increased pCR rates compared with non-TNBC, and those with pCR have excellent survival. However, patients with RD after neoadjuvant chemotherapy have significantly worse survival if they have TNBC compared with non-TNBC, particularly in the first 3 years.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Liedtke et al. (2008) studied this question.

synapsesocial.com/papers/69d6ceb9733a2b54c8aa84a1https://doi.org/10.1200/jco.2007.14.4147
Ask AI
Helpful
Bookmark
Share
View Full Paper